What is PALI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PALI?

P/E (TTM) is n/a and 52-week range is $1.32 to $2.85 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PALI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PALI?

The company profile lists revenue (TTM) near $417K, net income (TTM) near $-881M, EPS (TTM) near $-0.64 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Palisade Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carlsbad, California, US, 173.6M shares outstanding, ISIN US6963894026 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Palisade Bio Inc

$PALI

Health Care · Biotechnology

IR Run Scenarios

$1.54

+6.21%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 14 full-time employees. The company went IPO on 2006-12-20. The firm is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The firm is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. The company utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Employees

Website

palisadebio.com/

IPO

2006-12-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)